PFSA (Profusa) Total Stockholders Equity: $-28.20 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PFSA Profusa Inc PFSA
8 GF Score
Price $0.91
! 3 Warning Signs
View Full Analysis

What is Profusa Total Stockholders Equity?

Profusa PFSA +0.15% 8 Total Stockholders Equity is $-28.20 Mil as of Mar. 2026. GuruFocus rates PFSA with a GF Score™ of 8/100. The stock has 3 warning signs investors should review.

Profusa's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-28.20 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Profusa's Book Value per Share for the quarter that ended in Mar. 2026 was $-296.82. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Profusa's Debt-to-Equity for the quarter that ended in Mar. 2026 was -0.44.


Profusa  (NAS:PFSA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Profusa's Book Value per Share for the quarter that ended in Mar. 2026 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Profusa's Debt-to-Equity for the quarter that ended in Mar. 2026 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Profusa Total Stockholders Equity Related Terms


Profusa Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Profusa's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Profusa Total Stockholders Equity Chart

Profusa Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
-83.66 -99.77 -110.00 -119.21 -26.66

Profusa Quarterly Data
Dec21 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -121.92 -21.18 -33.96 -26.66 -28.20
PFSA
8GF Score
Profusa Inc PFSA
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $-28.20 Mil mean?
Profusa (PFSA) has a Total Stockholders Equity of $-28.20 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Profusa and its competitors.
Is Profusa's Total Stockholders Equity too high?
Profusa's current Total Stockholders Equity is $-28.20 Mil. Overall, Profusa has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Profusa's Total Stockholders Equity compare to VTAK and RBOT?
Profusa's Total Stockholders Equity of $-28.20 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Profusa and its competitors. Profusa's current Total Stockholders Equity is $-28.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profusa stock overvalued right now?
Profusa (PFSA) has a current Total Stockholders Equity of $-28.20 Mil. The current Total Stockholders Equity is $-28.20 Mil. Profusa's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Profusa (PFSA), the current Total Stockholders Equity is $-28.20 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Profusa Business Description

Address 626 Bancroft Way, Suite A, Berkeley, CA, USA, 94710
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
8GF Score

Get the complete analysis for PFSA

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.91
Price